The Law Offices of Frank R. Cruz Announces Investigation of Amylyx Pharmaceuticals, Inc. (AMLX) on Behalf of InvestorsBusiness Wire • 02/14/24
AMYLYX PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLXBusiness Wire • 02/14/24
Lost Money on Amylyx Pharmaceuticals, Inc. (AMLX)? Join Class Action Suit Seeking Recovery – Contact Levi & KorsinskyAccesswire • 02/13/24
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc. (AMLX) InvestorsBusiness Wire • 02/13/24
Shareholders that Lost Money on Amylyx Pharmaceuticals, Inc. (AMLX) Should Contact Levi & Korsinsky about Pending Class Action - AMLXAccesswire • 02/13/24
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLXPRNewsWire • 02/13/24
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMLXBusiness Wire • 02/12/24
AMLX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitBusiness Wire • 02/12/24
AMLX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Amylyx Class Action LawsuitBusiness Wire • 02/10/24
Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram SyndromeBusiness Wire • 02/08/24
Amylyx Therapeutics shares could soar if upcoming ALS trial succeeds, analysts sayProactive Investors • 01/03/24
Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)Business Wire • 12/22/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amylyx Pharmaceuticals, Inc. - AMLXPRNewsWire • 12/19/23
Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALSBusiness Wire • 12/04/23
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 11/29/23